Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
eNq1mF1v2jAUhu/5FVHuSRooo0yBamPthtRqjII27aYyyaGYBTs9tvnor59D6EYnR10NvoztvD72ef34yPHlZpl5K0BBOev6UXDme8ASnlL20PUn4+v6hX/Zq8ULsiIHw9rBWRA1fC/JiBBdv+gNpkCYCH7c3nwC/T+g36t5MZ8uIJEvxilJs+ALEfNbkhdjvHjFaeotQc552vVzJXetXiwk6ih6a46/RE4SiMN9y2Hv4v78sD0OC7H/UFUC8IawB6MoMCvNRCECk30i4YHjtiLeppU2FSMQXGECQyLnQ+QrmkJqnGJGMgFWk8zW6R3gKgNZTGIUDxfJUliJkwXZjOBxYA76g+7ty42sn9WjdrsTdZqd81arYZdcPNgqcxb0IsLkPmq2Ou3zVggsXG7503YJlrkZcpQkc5QVKvovjeVoHoTHV7OfUpFnZBssRG67VQSJ7gbUx9/dQooVjFEDKdN79o8+U1kWvjHqyR4XjiIuaNTniskKalyPbDeiz5mETXVG7UAnN3svUhCnk33izAz5oZpmNLFFmoaOAiEno0E10U4Jg49EwATd0eA7ZSlfi9NT5jCrjqLPd6A0iuaYRveNzsW7qNWyPkQ/tYUqbpgrhTyHUPOHimOwMmAzfixQtCvNUs+ePJkdd3UOT0gGFZVO3ZIt2ofPhZkzp7s7RWWHUfTz1djWHt8U4PZu92mUpmn3T2LtwOuC5tqMlYG/3drlCXdSAys0k2MuZS7eh+F6vQ7mRNQF0bsUzPDkZD+4TN1V4E5u7LKCKenoKPRpee29LUO2J+21O/3YOnX//74eNs4hUcERuSih7Aydg6vT0/hvkeos7OELeribZldQEkk5c1XoqKlR8Tj+67yya9SA+Dqb0YoXkUpfxmH5GtOrxWHxEtOr/QbM4eWM
x3kG4WNk2x1yxzwr
